GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (OTCPK:GLAXF) » Definitions » Cyclically Adjusted FCF per Share

GSK (GLAXF) Cyclically Adjusted FCF per Share : $1.92 (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is GSK Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

GSK's adjusted free cash flow per share for the three months ended in Mar. 2025 was $0.218. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $1.92 for the trailing ten years ended in Mar. 2025.

During the past 12 months, GSK's average Cyclically Adjusted FCF Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 3.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 3.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of GSK was 83.40% per year. The lowest was -0.60% per year. And the median was 5.05% per year.

As of today (2025-05-02), GSK's current stock price is $18.95. GSK's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was $1.92. GSK's Cyclically Adjusted Price-to-FCF of today is 9.87.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of GSK was 16.26. The lowest was 9.23. And the median was 12.60.


GSK Cyclically Adjusted FCF per Share Historical Data

The historical data trend for GSK's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted FCF per Share Chart

GSK Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.61 1.71 1.70 1.76 1.75

GSK Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.73 1.78 1.86 1.75 1.92

Competitive Comparison of GSK's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted Price-to-FCF falls into.


;
;

GSK Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GSK's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.218/135.6000*135.6000
=0.218

Current CPI (Mar. 2025) = 135.6000.

GSK Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.079 100.100 -0.107
201509 0.015 100.200 0.020
201512 0.312 100.400 0.421
201603 -0.042 100.400 -0.057
201606 0.277 101.000 0.372
201609 0.426 101.500 0.569
201612 0.702 102.200 0.931
201703 0.228 102.700 0.301
201706 0.130 103.500 0.170
201709 0.473 104.300 0.615
201712 0.739 105.000 0.954
201803 0.179 105.100 0.231
201806 0.331 105.900 0.424
201809 0.541 106.600 0.688
201812 1.106 107.100 1.400
201903 0.119 107.000 0.151
201906 0.239 107.900 0.300
201909 0.635 108.400 0.794
201912 0.870 108.500 1.087
202003 0.192 108.600 0.240
202006 0.734 108.800 0.915
202009 0.068 109.200 0.084
202012 1.100 109.400 1.363
202103 -0.008 109.700 -0.010
202106 0.256 111.400 0.312
202109 0.462 112.400 0.557
202112 1.054 114.700 1.246
202203 0.639 116.500 0.744
202206 0.286 120.500 0.322
202209 0.233 122.300 0.258
202212 0.344 125.300 0.372
202303 -0.141 126.800 -0.151
202306 0.238 129.400 0.249
202309 0.516 130.100 0.538
202312 0.741 130.500 0.770
202403 0.122 131.600 0.126
202406 0.207 133.000 0.211
202409 0.419 133.500 0.426
202412 0.363 135.100 0.364
202503 0.218 135.600 0.218

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


GSK  (OTCPK:GLAXF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

GSK's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=18.95/1.92
=9.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of GSK was 16.26. The lowest was 9.23. And the median was 12.60.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


GSK Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK Business Description

Industry
Address
79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.